Testing a new cancer medication alone and combined with immunotherapy

Plain-English translation of NCT06332755 on ClinicalTrials.gov ↗ · Source last updated November 2025 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

This is one of the first times this treatment has been tested in people.

What is this trial?

This is an early-stage trial testing a new experimental drug called LB-LR1109 in people with advanced cancers. The study will give the medication alone to patients with various solid tumors (like lung cancer, head and neck cancer, kidney cancer, bladder cancer, or melanoma), and will test the medication combined with an existing immunotherapy drug in patients with advanced lung cancer. Researchers want to find the safest and most effective dose, and to understand how the medication works in the body.

Many people with advanced cancers have limited treatment options, especially after standard therapies stop working or cause too many side effects. This medication represents a completely new approach to fighting cancer, and this trial is designed to see if it could offer hope to patients who need new options.

Do you qualify?

You likely qualify if…

you are 18 years old or older
you have been diagnosed with advanced or metastatic cancer (lung, head and neck, kidney, bladder, or melanoma) that has stopped responding to standard treatments or you cannot tolerate them
you have an Eastern Cooperative Oncology Group performance status score of 0 or 1, meaning you are able to carry out most normal daily activities
you have a life expectancy of at least 12 weeks
you have adequate organ function as determined by blood tests and other medical assessments
you are willing to use effective contraception during the study if you have childbearing potential

You likely don't qualify if…

you have significant heart disease or heart failure
you have brain tumors or cancer that has spread to your brain or spinal fluid that have not been treated or are unstable
you have another active cancer at the same time
you have had a life-threatening reaction to previous immunotherapy
you have an active autoimmune disease
you are pregnant, breastfeeding, or planning to conceive during the study or within 6 months after treatment ends

What participation looks like

Participants will visit the study site regularly to receive the medication (either alone or combined with another drug) and undergo blood tests, imaging scans, and other assessments to monitor safety and how their cancer responds. The study starts with small doses that gradually increase in subsequent groups of patients to find the right dose. Your doctor will closely watch for any side effects and adjust your treatment as needed based on how your body responds.

AI-generated summary from trial data · Jun 30, 2026 · Not medical advice

Testing a new cancer medication alone and combined with immunotherapy

What is this trial?

Do you qualify?

What participation looks like

Trial locations